epistaxis, septal perforation, and nasal congestion, which may affect nasal functioning and patient satisfaction with surgery. 6, 7, 15, 24 Central to the effort of determining the impact of rhinological morbidity on QOL is the development of a validated nasal morbidity instrument constructed specifically for the population undergoing endonasal skull base surgery.
Despite the proliferation and widespread adoption of endonasal skull base techniques, only recently have centers begun to investigate QOL concerns. 4, 10, 20, 21 Current reports are limited by the use of QOL scales that either do not assess nasal complaints 13 or were not developed or validated for endonasal skull base surgery. 13, 17, 22 Furthermore, neurosurgeons should be familiar with the nasal morbidity of these techniques to aid in preoperative and postoperative patient counseling and to help place their approach-related morbidity in the context of open skull base techniques. Claims have been made that endonasal surgery is "minimally invasive," but this has not been rigorously evaluated. A better understanding of the morbidity with this type of surgery is needed, as these techniques are now a standard part of the neurosurgical skull base armamentarium. In this study, we describe the development of the first approach-specific rhinological morbidity instrument for endonasal skull base surgery, the ASK Nasal-12, to complement other multidimensional QOL scales. This research effort used a multistep validation process that included creating a preliminary scale, 18 refining and expanding the instrument based on patient and expert feedback, and completing final validation in a multicenter prospective study.
Methods
This prospective multicenter study was approved by the institutional review boards at the participating institutions and registered with ClinicalTrials.gov (no. NCT01504399).
Patient Population
Eligible patients were consecutive English-or Spanish-speaking adults identified in the outpatient neurosurgical clinics at 3 skull base centers (Barrow Neurological Institute, Northshore University HealthSystem, and the John Wayne Cancer Institute) between October 2011 and July 2012. These patients had sellar pathology and a planned primary or secondary endonasal surgical approach using the transsphenoidal corridor. Patients with a history of prior radiotherapy to the paranasal sinus region or skull base were excluded. A total of 146 patients were screened for eligibility; 38 patients were not eligible for the study and 4 patients declined to participate.
Survey Administration
The survey was self-administered by patients within 2 weeks before surgery in the neurosurgical clinic and then at the first postoperative clinic visit 2-4 weeks after surgery. A research nurse provided the written instrument to the patient and was available for assistance. Survey responses were collated by the research nurse and entered into an Excel database for analysis.
Statistical Analysis
The strategy of selecting items for inclusion in the scale and validation of the scale was based on the methods used for development of the ASBQ and SNOT instruments. 12, 17 Exploratory factor analyses were conducted using maximum likelihood estimation. Variance accounted for and factor loadings presented are from the varimax rotated model. Internal consistency of the ASK Nasal-12 was determined using the Cronbach a.
9 Discriminant validity was evaluated at the item level and at the subscale level. Paired sample t-tests were used to calculate discriminant validity of our measure from pre-to postsurgery to examine the discrimination of each item. Effect sizes were obtained using a standardized response mean from t-tests. Concurrent validity was measured using the Spearman rho (r) correlation between the overall nasal functioning item and the mean of the total scale calculated without the overall functioning item. Test-retest reliability was measured by the average intraclass correlation coefficient. Statistical evaluation was performed by a doctorally trained biostatistician (K.C.) using SPSS version 20.
Results

Instrument Development and Content Validation
The ASK Nasal-12 was developed using a multistep process outlined in Fig. 1 . As the first step, a preliminary 9-item tool was developed. 18 During the validation process of this instrument, we discovered opportunities for enhancements, and therefore initiated the study reported herein to improve the scale. As part of this process, we engaged 4 additional subject matter experts in otolaryngology and neurosurgery, learned from the critiques of reviewers during the formal manuscript review process, conducted patient exit interviews for feedback, and reexamined current literature that had been published since the beginning of this project. 10, 21 As a result of this process, we made 3 main modifications to the preliminary instrument. First, we created a larger pool of questions addressing potential patient complaints that might impact QOL. Second, we expanded the 5-point rating scale to a 6-point rating scale to facilitate better discrimination of mild to moderate symptoms; we learned in the first study that most patients rated their symptoms as mild to moderate. Third, we changed the rating scale to one based on symptom severity rather than symptom frequency.
A revised pool of 23 questions focusing on common postoperative nasal complaints was developed. Patients were asked to score the severity of each symptom on a 6-point Likert scale (0 = no problem to 5 = very severe problem) and also to rank the 5 symptoms that were most important to them after surgery. One hundred four patients enrolled in the study and completed the preoperative questionnaire, and 100 (96%) patients completed the follow-up questionnaire within 2-4 weeks of surgery. Characteristics of the patient cohort are presented in Table 1 .
Preoperative, postoperative, and mean change scores were calculated for each question ( Fig. 2 ; Table 2 ) along with the percentage of patients ranking each symptom as important. Sensory symptoms, nasal obstruction symptoms, and nasal discharge symptoms had the greatest magnitude of worsening (p < 0.001), based on the mean change scores. In contrast, 4 symptoms demonstrated no significant change after surgery: dizziness, ear pain, nose bleeds, and eye tearing (p > 0.1). The symptoms rated most important to patients' lives included sense of smell, headache, and symptoms of nasal obstruction. Symptoms rated least important included nose whistling, teeth and ear pain, nose bleeds, and sound of voice.
Face Validity
Exploratory factor analysis was used to examine the factor structure of the instrument and to provide face validity of our measure. Factor loadings greater than 0.50 were retained, resulting in a 2-factor, 11-item measure. Latent constructs of the final measure were of a 2-factor solution, which we have labeled the symptom subscale and sensory subscale, and that accounted for 38.0% and 17.6% of variance, respectively. Together, these subscales accounted for 57.6% of the variance in the scores. The means, standard deviations, and standardized factor loadings for all items are presented in Table 2 . Patients' ratings of important symptoms were also considered in determining which items would be included in the final version. Although the factor loading for headache was less than the 0.50 cutoff, headache was rated the second most important symptom by patients and considered important by clinicians associated with the study. The final instrument included 8 of 10 symptoms ranked most important by patients and 9 of 10 symptoms with the greatest worsening after surgery. All symptoms included in the survey demonstrated statistically significant worsening following surgery.
Internal Consistency
Internal consistency of the ASK Nasal Inventory was determined using the Cronbach a before and after surgery for the initial 23-item survey, the final 12-item survey, and subscales of the final 12-item version. The Cronbach a (Table 2 ) ranged from 0.71 to 0.95, all suggestive of good internal consistency. Removal of any of the 12 questions did not significantly improve the internal consistency, suggesting that no question was substantially inconsistent with the others (data not shown).
Discriminant Validity
Values for 11 of the 12 items on the final scale were significantly higher after surgery, suggesting symptomatic worsening (Table 2) . Headache trended toward signifi- cance (p = 0.058). The mean total score was also significantly higher after surgery compared with before surgery (p < 0.001; Table 2 ). Together these findings indicate that the items discriminate postoperative nasal functioning from preoperative nasal functioning.
Effect Size
A standardized response mean was used to estimate effect size. The standardized response mean of our 12-item scale from presurgery to postsurgery was 0.84. The standardized response mean calculation suggests a large effect. 8 
Test-Retest Reliability
The ASK Nasal-12 was administered to 20 patients 3 months after surgery and then approximately 2 weeks later (median 15 days, interquartile range 13-19.75 days) to examine test-retest reliability. A significant intraclass correlation between responses emerged, providing evidence of instrument stability (intraclass correlation coefficient = 0.90, 95% CI 0.75-0.96; p < 0.001). In the reliability group, as expected, none of the items changed significantly from the first to the second survey administration.
Concurrent Validity
Concurrent validity was determined by correlation of the postoperative mean ASK Nasal-12 scores, calculated without the overall functioning item and with the overall functioning item postoperatively. 17, 18 There was a strong correlation between mean ASK Nasal-12 score and overall functioning (r = 0.64, 95% CI 0.51-0.74; p < 0.001).
Discussion
In this study we describe the development and multicenter validation of a unidimensional, site-specific, nasal morbidity instrument designed specifically for patients undergoing endonasal anterior cranial base surgery through the endonasal transsphenoidal corridor. The transsphenoidal corridor represents the most commonly used corridor for accessing skull base pathology. The ASK Nasal-12 was developed to assess patient perception of nasal morbidity, one of the primary sources of morbidity after endonasal surgery. The validation process narrowed a pool of 23 questions to 12 questions that were most important to patients and that reflected significant worsening after surgery. This prospective study demonstrates that the final 12-item scale is sensitive to clinical change and fulfills psychometric criteria for internal consistency, discriminant validity, test-retest reliability, and concurrent validity.
The ASK Nasal-12 represents the culmination of a multistep and iterative process to develop a validated nasal morbidity instrument for endonasal skull base surgery. Based on our initial experience with the ASK Nasal-9 18 and by incorporating patient and expert feedback, we went back to the drawing board and rebuilt the tool by expanding the question pool, engaging additional subject matter experts, and modifying its symptom assessment to incorporate severity rather than just frequency. We believe that the iterative process we used to validate the tool adds to its validity as the process allowed for enhancements to be made along the way. The ASK Nasal-12 was completely revalidated in a rigorous multicenter nasal morbidity study, the first of its kind in endonasal skull base surgery.
The questions regarding nasal morbidity in endonasal skull base surgery have only recently begun to be addressed despite the proliferation and general acceptance of these techniques. 10, 12, 16, [19] [20] [21] 23, 25 These studies have at least 1 of several important limitations, including retrospective analysis of data, interpretation of unpaired postoperative data, use of nonvalidated outcome measures, and application of scales developed for other disease entities in unrelated patient populations. In this study, we sought to address the latter 2 limitations. It is our contention that QOL studies in endonasal skull base surgery would benefit from the development of an instrument designed and validated with this population of patients in mind.
The ASK Nasal-12 scale offers several improvements to the QOL scales used previously. For example, the most * All values given as mean ± SD unless otherwise indicated. † Percentage of patients ranking the symptom as important to them after surgery. ‡ Probability values < 0.001 for all symptom subscale variables, except for headache (p = 0.058). § Probability values < 0.001 for all variables. ¶ Probability values < 0.001 for sneezing, facial pain pressure, sound of voice, cough, numbness in upper front teeth, and ear fullness; p < 0.01 for foul smell inside nose; all other variables not significant.
commonly used rhinological scale used is the SNOT, a disease-specific instrument developed for assessment of QOL in patients with rhinosinusitis. 17, 22 Our work suggests that its primary limitation is one of content validation. The SNOT does not assess some of the most relevant postoperative symptoms associated with endonasal skull base surgery and does evaluate symptoms that are less important to our patients. For instance, the SNOT-20 does not assess for sense of smell and taste, headache, dried nasal crusts, and nasal whistling, which our work demonstrated are important to patients and which worsen initially after surgery. However, the SNOT-20 does assess for ear-related symptoms and sneezing, which are important in rhinosinusitis, but which our work suggests are not as important to patients undergoing endonasal skull base surgery.
The other commonly used scale is the ASBQ. The ASBQ is a 35-question disease-specific multidimensional instrument developed by Gil and colleagues 13 to assess QOL in patients with sinonasal and anterior cranial base pathology addressed through an open cranial approach. This well-validated scale assesses 6 domains including performance, physical functioning, vitality, emotion, pain, and specific symptoms. It is a valuable tool for improving our understanding of QOL after skull base surgery. However, its primary shortcoming in its application to endonasal surgery is that it does not specifically assess nasal morbidity, one of the key sources of morbidity after this type of surgery.
1,2,11-14 A nasal morbidity scale such as the ASK Nasal-12, which complements existing multidimensional QOL instruments, may be a useful clinical and research tool.
The clinical application of the ASK Nasal-12 requires additional comment. In the ASK Nasal-12, each question is assumed to be weighted equally and scored on a 6-point Likert scale (0-5). The total score is obtained by summing the scores of each question, with a total possible score ranging from 0 to 60. Higher scores indicate higher patient-reported nasal morbidity. The scale can be completed in person, by email, or over the phone in about 2 minutes. We have also translated it into Spanish. Exploratory factor analysis suggested that the scale has 2 subdomains, but 1 domain only includes 2 items. We recommend reporting results as an overall score rather than breaking the scale into subdomains until understanding of the subdomains improves. Finally, the ASK Nasal-12 was developed for use in conjunction with other well-validated multidimensional QOL scales, such as the ASBQ or Short-Form Health Surveys. 3, 5 Because these excellent multidimensional tools already exist, we did not believe that it was necessary to develop another multidimensional tool; rather, we focused on studying nasal morbidity.
We envision that the ASK Nasal-12 can be used for future research endeavors and for the longitudinal evaluation of patients in routine clinical practice. Our hope is that the ASK Nasal-12 will help us to meaningfully address some of the more intriguing technical questions associated with endonasal skull base surgery, such as differences in nasal morbidity between microscopic approaches and endoscopic approaches, the morbidity of middle turbinate resection versus outfracture, and a comparison of uninostril versus binostril techniques. To address some of these questions, the ASK Nasal-12 is being applied as 1 end point in an ongoing multicenter QOL study. This study will address the rhinological outcomes of microscopic and fully endoscopic endonasal techniques and is being conducted at 4 US centers.
Conclusions
In this prospective study, we developed and validated a site-specific, unidimensional QOL scale that assesses nasal morbidity after endonasal skull base surgery. Our data demonstrate that the ASK Nasal-12 is sensitive to clinical change and fulfills parameters for psychometric validity. The ASK Nasal-12 addresses the limitations of currently used sinonasal outcome scales and multidimensional QOL measures. It can be used as a complement to other QOL instruments for the purposes of research and clinical practice. The ASK Nasal-12 is being applied as 1 end point in an ongoing multicenter QOL study. 
